You want to know more?

Check out our paper for more information on what’s in the pipeline and the challenges linked to the development of new methods. There is also a policy section that explains why we urgently need the EU and Member States to step up their investments in contraceptive innovation. After all, this would deliver major public health and economic benefits, competitive scientific breakthroughs, but most importantly: better contraceptives!

Switch positions… not only in bed!

Novel male contraceptives are not meant to replace women’s contraceptive options and strategies, but rather to expand everyone’s: more choice, more agency, more equality.

Condoms. Vasectomy. That’s it for men?

Women still carry a disproportionate burden for preventing unintended pregnancies, facing the potential physical, financial, and sometimes psychological consequences of contraceptive use.

Men are stuck with exactly two contraceptive options since the 1960s. Less than 2% of global contraceptive R&D funding goes into male contraceptive methods.

Science is cooking – but the missing ingredient is funding.

NES/T Gel, ADAM, YCT-529, PLAN A, Andro-Switch… Promising new male contraceptive options are advancing through the research and development pipeline – but not fast enough. What they lack is adequate funding, regulatory support, and political will to make those complex and expensive last stages of development happen.